A phase 1, single-blind, randomized, placebo-controlled trial started by Palatin Technologies is aimed at evaluating the efficiency of AZD282 for treating obesity.
The discovery, development, and commercialization of melanocortin receptor-targeting compounds for the treatment of obesity, diabetes, and related metabolic syndromes is said to be facilitated by the research and licensing deal signed between Palatin with AstraZeneca.
Nearly 90 male participants are expected to be recruited by the company for the trial. In addition to royalties on sales of approved products, AstraZeneca will be in charge of making landmark payments to Palatin first upon meeting development and regulatory targets, followed by additional payments on achieving sales targets.
The strategic partnership between the 2 companies permits AstraZeneca to further product discovery, commercialization, and take up the development costs.